- Home
- GEN vs DVA Comparison
GEN vs DVA Comparison
Compare GEN & DVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GEN
- DVA
- Stock Information
- Founded
- GEN 1982
- DVA 1994
- Country
- GEN United States
- DVA United States
- Employees
- GEN N/A
- DVA N/A
- Industry
- GEN Computer Software: Prepackaged Software
- DVA Misc Health and Biotechnology Services
- Sector
- GEN Technology
- DVA Health Care
- Exchange
- GEN Nasdaq
- DVA Nasdaq
- Market Cap
- GEN 17.3B
- DVA 15.2B
- IPO Year
- GEN N/A
- DVA 1995
- Fundamental
- Price
- GEN $27.05
- DVA $142.30
- Analyst Decision
- GEN Buy
- DVA Hold
- Analyst Count
- GEN 4
- DVA 5
- Target Price
- GEN $29.00
- DVA $154.40
- AVG Volume (30 Days)
- GEN 3.4M
- DVA 1.1M
- Earning Date
- GEN 01-30-2025
- DVA 02-13-2025
- Dividend Yield
- GEN 1.85%
- DVA N/A
- EPS Growth
- GEN N/A
- DVA 44.61
- EPS
- GEN 1.02
- DVA 10.73
- Revenue
- GEN $3,901,000,000.00
- DVA $12,815,550,000.00
- Revenue This Year
- GEN $3.99
- DVA $4.69
- Revenue Next Year
- GEN $3.43
- DVA $3.54
- P/E Ratio
- GEN $26.54
- DVA $13.27
- Revenue Growth
- GEN 3.12
- DVA 5.56
- 52 Week Low
- GEN $19.58
- DVA $122.65
- 52 Week High
- GEN $31.72
- DVA $179.60
- Technical
- Relative Strength Index (RSI)
- GEN 41.91
- DVA 25.38
- Support Level
- GEN $26.88
- DVA $150.11
- Resistance Level
- GEN $28.09
- DVA $178.38
- Average True Range (ATR)
- GEN 0.59
- DVA 4.89
- MACD
- GEN -0.01
- DVA -4.14
- Stochastic Oscillator
- GEN 31.82
- DVA 3.47
About GEN Gen Digital Inc.
Gen is a cybersecurity pure-play that offers security, identity protection, and privacy solutions to individual consumers. The firm's cyber safety offerings, via brands such as Norton, Avast, and LifeLock, have long maintained their positions as some of the most recognizable consumer-focused security and identity-protection products.
About DVA DaVita Inc.
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,000 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives about two thirds of U.S. sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.